What is a CD38 monoclonal antibody?

A substance that binds to a protein called CD38, which is found on some types of blood cells and in high levels on some cancer cells, including myeloma cells. Anti-CD38 monoclonal antibody may block the CD38 protein and help the immune system kill cancer cells.

What is CD38 in multiple myeloma?

CD38 is a protein that is primarily found on the surface of multiple myeloma cells. Other cells carry CD38, including red blood cells, although at lower levels. The protein’s strong association with multiple myeloma cells is what makes CD38 a treatment target.

Is Daratumumab anti-CD38?

The recently approved anti-CD38 monoclonal antibody daratumumab (DARA) provides a unique therapeutic strategy that more selectively targets plasma cells in patients with plasma cell myeloma. While DARA recognizes and removes malignant plasma cells, red blood cells (RBCs) also express CD38.

How is Isatuximab different than daratumumab?

Additionally, isatuximab inhibits CD38 enzymatic activity more effectively than daratumumab3, resulting in decreased adenosine production, and may alleviate the immunosuppressive microenvironment of the bone marrow niche in MM patients4.

What type of antibody is daratumumab?

Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells.

Is daratumumab the same as Darzalex?

DARZALEX® (daratumumab) is a prescription medicine used to treat a type of blood cancer called multiple myeloma. DARZALEX® is not chemotherapy. It is a targeted monoclonal antibody that helps slow or stop the progression of multiple myeloma in several ways.

What does Daratumumab treat?

Daratumumab injection is used alone or in combination with other medications to treat multiple myeloma (a type of cancer of the bone marrow) in newly diagnosed people and in people who have not improved with treatment or who have improved after treatment with other medications but the condition returned.

Why is BCMA a good target for multiple myeloma?

Abstract. B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs).

Is CD38 negative good?

In contrast, the CD38- negative group required minimal or no treatment, remained treatment-free for a longer time period and had prolonged survival (P < 0.05). CD38 expression was a robust marker in the majority of patients in that it was stable over time and not significantly influenced by chemotherapy.

How long is daratumumab effective?

DARZALEX® can affect the results of blood tests to match your blood type. These changes can last for up to 6 months after your final dose of DARZALEX®.

What are side effects of isatuximab?

Isatuximab side effects

• easy bruising, unusual bleeding, purple or red spots under your skin;
• low white blood cell counts–fever, mouth sores, skin sores, sore throat, cough, trouble breathing;
• low red blood cells (anemia)–pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; or.